INFLUENCE OF THE HEART RATE ON THE QUALITY OF LIFE AND SEVERITY OF ARRHYTHMIA SYMPTOMS IN PATIENTS WITH A PERMANENT ATRIAL FIBRILLATION NON-VALVULAR ETIOLOGY
DOI:
https://doi.org/10.11603/2415-8798.2017.3.8081Keywords:
permanent atrial fibrillation, heart rate control, quality of life, symptoms severity of arrhythmia.Abstract
Atrial fibrillation (AF) is the most common chronic cardiac rhythm disorder and is rightly considered a 21st century epidemic. AF is usually associated with life quality worsening. That is why its improvement is one of the main tasks in the treatment of this group of patients.
The aim of the study – to estimate the dynamic changes in the quality of life and the severity of arrhythmia symptoms (SAS ) in patients with a permanent atrial fibrillation non-valvular etiology during treatment with β-blockers (BB ), determination the critical value of the heart rate as a negative dynamic predictor of the life quality and SAS during 6 month monitoring, identification the preference for one of the HR control strategies.
Material and Methods. 30 patients are consistently included in this study. The duration of observation was 238.3±17.0 days, the design consisted in 3 visits. Titration of the BB dose lasted 67.7±10.3 days (the interval between the first and second visits). Reception of the maximum or maximum tolerable dose of BB lasted 170.6±17.7 days (the interval between the second and final visits). ECG recording, Holter ECG, assessment of QoL and SAS were conducted during each of the visits.
Results and Discussion. During follow-up period the resting heart rate in beats/min and ms by ECG on the first and second visits decreased significantly. At the same time, according to Holter ECG data, such a pattern was not found. When assessing life quality and SAS values, the number of points for the Minnesota living with heart failure questionnaire (MLH FQ) was significantly reduced at the 3rd visit, and the score for the physical health factor in the same questionnaire also decreased already at the 2nd visit. The conducted correlation analysis revealed a relationship between the score on the EHRA and SA F SAS scales with the mean daily HR value according to 24 h Holter ECG. When comparing both strategies strict control showed a significant advantage for the duration of the minimum, maximum and average RR intervals in beats/min and increasing their duration in ms, and consequently, the decrease in heart rate, according to ECG data (1, 2, 3 visits); decrease (1, 2, 3 visits), the mean maximum (1, 2, 3 visits), the mean minimum (1, 2, 3 visits), the mean in the active period (1, 2, 3 visits), the mean passive period (1 visit) heart rate in beats/min, circadian index (CI) (1, 2 visits), increase mean daily (1, 2, 3 visits), the mean maximum (1, 2, 3 visits), the mean minimum (1, 2, 3 visits), the mean in the active period (2, 3 visits), the mean in the passive period (1 visit), heart rate in ms according to the Holter ECG data.
Conclusions. In patients with PA F non-valvular etiology during 6-month follow-up period Holter ECG was an objective indicator of heart rate control. Usage of BB for PA F has a positive effect on QoL by reducing the intensity of HF symptoms for the MLH FQ by improving the physical component of health. Fixed during Holter ECG mean daily HR > 91 beats/min is a predictor of SAS negative dynamics of the EHRA and SA F scales. Strict heart rate control shows a more pronounced effect on heart rate according to ECG and Holter ECG. None of the heart rate control strategies has demonstrated its benefits in terms of improving life quality and SAS .
References
Sychov, O. S., Kovalenko, V. M., Dziak, H. V., Korkushko, A. V., Bobrov, V. O., Hryn, V. K., . . . Lobko, O. O. (2011). Diahnostyka ta likuvannia fibryliatsii peredserd. Rekomendatsii robochoi hrupy po porushenniam sertsevoho rytmu Asotsiatsii kardiolohiv Ukrainy. [Diagnosis and treatment of atrial fibrillation. Recommendations of the Working Group on Cardiac Arrhythmia of the Association of Cardiologists of Ukraine.]. Kyiv. [in Ukrainian]
Zoni-Berisso, M., Lercari, F., Carazza, T., & Domenicucci, S. (2014). Epidemiology of atrial fibrillation: European Perspective. Clinical Epidemiology, 6, 213-220. doi:10.2147/CLEP.S47385
Björck, S., Palaszewski, B., Friberg, L., & Bergfeldt, L. (2013). Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke, 44(11), 3103-3108. doi:10.1161/STROKEAHA.113.002329
Haim, M., Hoshen, M., Reges, O., Rabi, Y., Balicer, R., & Leibowitz, M. (2015). Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. Journal of the American Heart Association, 4(1), E001486. doi:10.1161/JAHA.114.001486
Chiang, C. E., Naditch-Brûlé, L., Murin, J., Goethals, M., Inoue, H., O'Neill, J., . . . Steg, P. G. (2012). Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circulation: Arrhythmia and Electrophysiology, 5(4), 632-639. doi:10.1161/CIRCEP.112.970749
Murin, J., Naditch-Brûlé, L., Brette, S., Chiang, C. E., O'Neill, J., & Steg, P. G. (2014). Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey. PLoS One, 9(1), E86443. doi:10.1371/journal.pone.0086443
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., . . . Zeppenfeld, K. (2016). ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 37(38), 2893-2962. doi:10.1093/eurheartj/ehw210
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., . . . Zamorano, J. L. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), 2129-2200. doi:10.1093/eurheartj/ehw128
Mulder, B. A., Veldhuisen, D. J., Van, Crijns, H. J., Tijssen, J. G., Hillege, H. L., Alings, M., . . . Gelder, I. C., Van. (2013). Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post-hoc analysis of the RACE II study. European Journal of Heart Failure, 15(11), 1311-1318. doi:10.1093/eurjhf/hft093
Gelder, I. C., Van, Groenveld, H. F., Crijns, H. J., Tuininga, Y. S., Tijssen, J. G., Alings, A. M., . . . Berg, M. P., Van Den. (2010). Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. The New England Journal of Medicine, 362, 1363-1373. doi:10.1056/NEJMoa1001337
Chudzik, M., Cygankiewicz, I., Klimczak, A., Lewek, J., Bartczak, K., & Wranicz, J. K. (2014). Short-term ECG recordings for heart rate assessment in patients with chronic atrial fibrillation. Archives of Medical Science, 10(4), 676-683. doi:10.5114/aoms.2014.44859
Srisukwattana, A., & Krittayaphong, R. (2012). Comparison of rate assessment between resting heart rate and 24-hour Holter monitoring in patients with chronic atrial fibrillation. Journal of the Medical Association of Thailand, 95(2), 111-116. Retrieved from http://www.jmatonline.com/index.php/jmat/article/view/1798
Jaber, J., Cirenza, C., Jaber, J., Amaral, A., Almeida Sousa, J. M., De, Oliveira Filho, J. A., & Paola, A. A., De. (2010). Influence of heart rate on quality of life in patients with chronic atrial fibrillation. Clinical Cardiology, 33(4), E28-E32. doi:10.1002/clc.20528
Nazlı, C., Kahya Eren, N., Yakar Tülüce, S., Koçağra Yağız, İ. G., Kılıçaslan, B., & Kocabaş, U. (2016). Impaired quality of life in patients with intermittent atrial fibrillation. The Anatolian Journal of Cardiology, 16(4), 250-255. doi:10.5152/AnatolJCardiol.2015.6144
Groenveld, H. F., Crijns, H. J., Berg, M. P., Van Den, Sonderen, E., Van, Alings, A. M., Tijssen, J. G., . . . Veldhuisen, D. J., Van. (2011). The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. Journal of the American College of Cardiology, 58(17), 1795-1803. doi:10.1016/j.jacc.2011.06.055
Luderitz, B., & Jung, W. (2000). Quality of life in patients with atrial fibrillation. Archives of Internal Medicine, 160(12), 1749-1757. doi:10.1001/archinte.160.12.1749
Thrall, G., Lane, D., Carroll, D., & Lip, G. Y. (2006). Quality of life in patients with atrial fibrillation: a systematic review. The American Journal of Medicine, 119(5), 448.e1-448.e19. doi:10.1016/j.amjmed.2005.10.057
Camm, A. J., Kirchhof, P., Lip, G. Y., Schotten, U., Savelieva, I., Ernst, S., . . . Rutten, F. H. (2010). Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 31(19), 2369-2429. doi:10.1093/eurheartj/ehq278
Tsounis, D., Ioannidis, A., Bouras, G., Raikou, M., Giannopoulos, G., Deftereos, S., . . . Stefanadis, C. (2014). Assessment of health-related quality of life in a greek symptomatic population with atrial fibrillation: correlation with functional status and echocardiographic indices. The Hellenic Journal of Cardiology, 55(6), 475-485. Retrieved from http://www.hellenicjcardiol.org/archive/full_text/2014/6/2014_6_475.pdf
Vermond, R. A., Crijns, H. J., Tijssen, J. G., Alings, A. M., Berg, M. P., Van Den, Hillege, H. L., . . . Rienstra, M. (2014). Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. Europace, 16(10), 1417-1425. doi:10.1093/europace/euu151
Kirchhof, P., Auricchio, A., Bax, J., Crijns, H., Camm, J., Diener, H. C., . . . Breithardt, G. (2007). Outcome parameters for trials in atrial fibrillation: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. Europace, 9(11), 1006-1023. doi:10.1093/europace/eum191
Dorian, P., Cvitkovic, S. S., Kerr, C. R., Crystal, E., Gillis, A. M., Guerra, P. G., . . . Wyse, D. G. (2006). A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: The CCS-SAF Scale. Canadian Journal of Cardiology, 22(5), 383-386. doi:10.1016/s0828-282x(06)70922-9
Dorian, P., Guerra, P. G., Kerr, C. R., Odonnell, S. S., Crystal, E., Gillis, A. M., . . . Wyse, D. G. (2009). Validation of a New Simple Scale to Measure Symptoms in Atrial Fibrillation: The Canadian Cardiovascular Society Severity in Atrial Fibrillation Scale. Circulation: Arrhythmia and Electrophysiology, 2(3), 218-224. doi:10.1161/circep.108.812347
Healey, J. S., Parkash, R., Pollak, T., Tsang, T., & Dorian, P. (2011). Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Etiology and Initial Investigations. Canadian Journal of Cardiology, 27(1), 31-37. doi:10.1016/j.cjca.2010.11.015
Aliot, E., Botto, G. L., Crijns, H. J., & Kirchhof, P. (2014). Quality of life in patients with atrial fibrillation: how to assess it and how to improve it. Europace, 16(6), 787-796. doi:10.1093/europace/eut369
Rector, T. S., & Cohn, J. N. (1992). Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. American Heart Journal, 124(4), 1017-1025. doi:10.1016/0002-8703(92)90986-6
Garin, O., Herdman, M., Vilagut, G., Ferrer, M., Ribera, A., Rajmil, L., . . . Alonso, J. (2013). Assessing health-related quality of life in patients with heart failure: a systematic, standardized comparison of available measures. Heart Failure Reviews, 19(3), 359-367. doi:10.1007/s10741-013-9394-7
Hoekstra, T., Lesman-Leegte, I., Veldhuisen, D. J., Van, Sanderman, R., & Jaarsma, T. (2011). Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction. European Journal of Heart Failure, 13(9), 1013-1018. doi:10.1093/eurjhf/hfr072
Bilbao, A., Escobar, A., García-Perez, L., Navarro, G., & Quirós, R. (2016). The Minnesota living with heart failure questionnaire: comparison of different factor structures. Health and Quality of Life Outcomes, 14(1), 2-11. doi:10.1186/s12955-016-0425-7
Gillis, A. M., Verma, A., Talajic, M., Nattel, S., & Dorian, P. (2011). Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm Management. Canadian Journal of Cardiology, 27(1), 47-59. doi:10.1016/j.cjca.2010.11.001
Makarov, L. (2006). Circadian Index, as a Additional Parameter for Assessement of the Heart Rhythm in Patients With Heart Failure. ISHNE Heart Failure World-Wide Internet Symposium. doi:10.13140/RG.2.1.3204.6246
Ware, J. E., & Sherbourne, C. D. (1992). The MOS 36-ltem Short-Form Health Survey (SF-36). Medical Care, 30(6), 473-483. doi:10.1097/00005650-199206000-00002
Kitzman, D. W., Little, W. C., Brubaker, P. H., Anderson, R. T., Hundley, W. G., Marburger, C. T., . . . Stewart, K. P. (2002). Pathophysiological Characterization of Isolated Diastolic Heart Failure in Comparison to Systolic Heart Failure. The Journal of the American Medical Association, 288(17), 2144-2150. doi:10.1001/jama.288.17.2144
Badano, L. P., Albanese, M. C., Biaggio, P., De, Rozbowsky, P., Miani, D., Fresco, C., & Fioretti, P. M. (2004). Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction. Journal of the American Society of Echocardiography, 17(3), 253-261. doi:10.1016/j.echo.2003.11.002
Rector, T. S., Carson, P. E., Anand, I. S., Mcmurray, J. J., Zile, M. R., Mckelvie, R. S., . . . Massie, B. M. (2012). Assessment of Long-Term Effects of Irbesartan on Heart Failure With Preserved Ejection Fraction as Measured by the Minnesota Living With Heart Failure Questionnaire in the Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) Trial. Circulation: Heart Failure, 5(2), 217-225. doi:10.1161/circheartfailure.111.964221
Kato, N., Kinugawa, K., Seki, S., Shiga, T., Hatano, M., Yao, A., . . . Nagai, R. (2011). Quality of Life as an Independent Predictor for Cardiac Events and Death in Patients With Heart Failure. Circulation Journal, 75(7), 1661-1669. doi:10.1253/circj.cj-10-1308
Hoekstra, T., Jaarsma, T., Veldhuisen, D. J., Van, Hillege, H. L., Sanderman, R., & Lesman-Leegte, I. (2013). Quality of life and survival in patients with heart failure. European Journal of Heart Failure, 15(1), 94-102. doi:10.1093/eurjhf/hfs148
Lewis, E. F., Lamas, G. A., Omeara, E., Granger, C. B., Dunlap, M. E., Mckelvie, R. S., . . . Pfeffer, M. A. (2007). Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. European Journal of Heart Failure, 9(1), 83-91. doi:10.1016/j.ejheart.2006.10.012
Lainscak, M. (2004). Implementation of guidelines for management of heart failure in heart failure clinic: effects beyond pharmacological treatment. International Journal of Cardiology, 97(3), 411-416. doi:10.1016/j.ijcard.2003.10.031
González-Juanatey, J. R., Alegría Ezquerra, E., García Saavedra, V., Pérez Ojeda, G., Ruiz Ros, J. A., Espinosa Caliani, J. S., & Anguita Sánchez, M. (2003). Empleo de bisoprolol en la insuficiencia cardíaca. Resultados del estudio BISOCOR [Use of bisoprolol in heart failure. The BISOCOR observational study]. Revista Española de Cardiologia, 56(9), 873-879. doi:10.1157/13051614 [in Spanish]
Cohn, J. N., Fowler, M. B., Bristow, M. R., Colucci, W. S., Gilbert, E. M., Kinhal, V., . . . Lukas, M. A. (1997). Safety and efficacy of carvedilol in severe heart failure. Journal of Cardiac Failure, 3(3), 173-179. doi:10.1016/s1071-9164(97)90013-0
Silvet, H., Hawkins, L. A., & Jacobson, A. K. (2012). Heart Rate Control in Patients With Chronic Atrial Fibrillation and Heart Failure. Congestive Heart Failure, 19(1), 25-28. doi:10.1111/j.1751-7133.2012.00309.x
Downloads
Published
How to Cite
Issue
Section
License
Authors who sent their manuscript to "Вісник наукових досліджень. Bulletin of Scientific Research" Surgery agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
